Creative Biolabs has expanded its complement testing capabilities to help researchers overcome challenges in complement drug development through comprehensive complement activity assays, CH50 ...
Clinicogenomic landscape and outcomes of metastatic colorectal cancer patients with pathogenic GNAS variants. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...
Priority review for ravulizumab in IgA nephropathy could establish the first C5 complement inhibitor label in this indication, addressing substantial residual progression risk despite current standard ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する